Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Oct 29;9(11):3502. doi: 10.3390/jcm9113502

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

KIR2DL3 differential expression changes in the group of patients with myeloid neoplasia, where the expression decreased compared to the original value, and in a lymphoid group, with a higher expression of NK cells in patients than in the donor before HSCT (A). The FEAM (Fludarabine + Etoposid + Ara-C + Melphalan) protocol reduced the expression of KIR2DL3, unlike other conditioning regimens in the myeloid group (B). * statistically significant results p < 0.05; NS, without statistical significance (p > 0.05); outliers, ; Median, .

Inline graphic — KIR2DL3 differential expression changes in the group of patients with myeloid neoplasia, where the expression decreased compared to the original value, and in a lymphoid group, with a higher expression of NK cells in patients than in the donor before HSCT (A). The FEAM (Fludarabine + Etoposid + Ara-C + Melphalan) protocol reduced the expression of KIR2DL3, unlike other conditioning regimens in the myeloid group (B). * statistically significant results p < 0.05; NS, without statistical significance (p > 0.05); outliers, ; Median, .